Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 4Carcinoma, Transitional Cell 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Carcinoma, Renal Cell 2Urologic Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neoplasm Metastasis 1Microsatellite Instability 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Kidney Diseases 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Oxaliplatin 56Capecitabine 49Fluorouracil 37Cisplatin 37S 1 (combination) 23Paclitaxel 18Docetaxel 18Leucovorin 16pembrolizumab 13Irinotecan 12apatinib 11titanium silicide 9XELOX 9Trastuzumab 9Nivolumab 9Hyperthermic Intraperitoneal Chemotherapy 8Epirubicin 8Drug Therapy 8Tegafur 7Radiotherapy 6Neoadjuvant Therapy 6gimeracil 5Surgical Procedures, Operative 5Gastrectomy 5Chemotherapy, Adjuvant 5tislelizumab 4S-1 plus cisplatin 4Ramucirumab 4zolbetuximab 3sintilimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Stomach Neoplasms × avelumab × Clear all
NCT02625623 2020-11-24

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

EMD Serono

Phase 3 Completed
371 enrolled 18 charts
Gastrointestinal

Recurrence, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡